• All
  • Important
  • Financial Update
  • Fund Raise
  • Board Meeting
  • Dividend/Bonus
  • JV/Acquisition
  • Investor Meet
  • Insider Trade
  • Pledging
  • Others
    ALPHA TRIBE

    Glenmark Pharmaceuticals Limited — Updates, 21-03-2026: Press Release

    21-03-2026 | 12:28 am

    Glenmark launched GLIPIQ® (semaglutide) in India for Type 2 Diabetes, setting a new affordability benchmark for GLP-1 therapy. Weekly treatment starts at ₹325, significantly expanding patient access to advanced diabetes care.

    No comments yet. Be the first to comment!

    All announcements from Glenmark Pharmaceuticals Limited